635 results on '"Metersky, Mark L."'
Search Results
2. Association between bronchiectasis exacerbations and longitudinal changes in FEV1 in patients from the US bronchiectasis and NTM research registry
3. Nebulized hypertonic saline and positive expiratory pressure device use in patients with bronchiectasis: Analysis from the United States Bronchiectasis and NTM research registry
4. Severity of bronchiectasis predicts use of and adherence to high frequency chest wall oscillation therapy - Analysis from the United States Bronchiectasis and NTM research registry
5. Relationship Between In-Hospital Adverse Events and Hospital Performance on 30-Day All-cause Mortality and Readmission for Patients With Heart Failure
6. Characteristics of exacerbators in the US Bronchiectasis and NTM Research Registry: a cross-sectional study
7. The Impact of Tobacco Smoking in Bronchiectasis: Data from the United States Bronchiectasis and NTM Research Registry
8. Five-Year Outcomes Among U.S. Bronchiectasis and Nontuberculous Mycobacterial Registry Patients
9. Stenotrophomonas maltophilia in patients with bronchiectasis: An analysis of the US bronchiectasis and NTM Research Registry
10. Five-Year Outcomes among U.S. Bronchiectasis and NTM Research Registry Patients.
11. Time Trends in Patient Characteristics and In-Hospital Adverse Events for Primary Total Knee Arthroplasty in the United States: 2010-2017
12. Pseudomonas aeruginosa associated with severity of non-cystic fibrosis bronchiectasis measured by the modified bronchiectasis severity score (BSI) and the FACED: The US bronchiectasis and NTM Research Registry (BRR) study
13. Airway Clearance Techniques in Bronchiectasis: Analysis From the United States Bronchiectasis and Non-TB Mycobacteria Research Registry
14. Rates of Adverse Events in Hospitalized Patients After Summer-Time Resident Changeover in the United States: Is There a July Effect?
15. The Chronic Obstructive Pulmonary Disease (COPD)–Bronchiectasis Overlap Syndrome: Does My COPD Patient Have Bronchiectasis on Computed Tomography? “Frankly, My Dear, I Don’t Give a Damn!”
16. EFFICACY AND SAFETY OF DIPEPTIDYL PEPTIDASE-1 INHIBITION WITH BRENSOCATIB IN THE FREQUENT EXACERBATOR PHENOTYPE: A SUBGROUP ANALYSIS FROM THE WILLOW TRIAL
17. TRENDS IN RESPIRATORY CULTURES: A LOOK AT THE US BRONCHIECTASIS RESEARCH REGISTRY
18. LUNG FUNCTION OF PATIENTS WITH AN EOSINOPHILIC PHENOTYPE: AN ANALYSIS OF THE US BRONCHIECTASIS AND NTM RESEARCH REGISTRY
19. The Impact of Tobacco Smoking in Bronchiectasis: Data from the U.S. Bronchiectasis and Nontuberculous Mycobacteria Research Registry.
20. Inflammatory Activity of Epithelial Stem Cell Variants from Cystic Fibrosis Lung Is Not Resolved by CFTR Modulators
21. Dipeptidyl peptidase-1 inhibition in bronchiectasis with eosinophilic endotype in the WILLOW trial
22. Reply to Hassoun et al
23. Reply to Daniels et al.
24. Cloning a profibrotic stem cell variant in idiopathic pulmonary fibrosis
25. Management of Ventilator-Associated Pneumonia
26. National trends in the frequency of bladder catheterization and physician-diagnosed catheter-associated urinary tract infections: Results from the Medicare Patient Safety Monitoring System
27. Mechanisms and management of cough in interstitial lung disease.
28. Inflammatory Activity of Epithelial Stem Cell Variants from Cystic Fibrosis Lungs Is Not Resolved by CFTR Modulators.
29. Health care–associated pneumonia in the intensive care unit: Guideline-concordant antibiotics and outcomes
30. Benefit−risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis
31. SARS-CoV-2 Antibody Dynamics in Healthcare Workers after mRNA Vaccination
32. The 6th World Bronchiectasis and Nontuberculous Mycobacteria Conference Abstract Presentations
33. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society
34. Temporal trends in postoperative and ventilator-associated pneumonia in the United States
35. Less Is More: A 7-Day Course of Antibiotics Is the Evidence-Based Treatment forPseudomonas aeruginosaVentilator-Associated Pneumonia
36. Racial and Ethnic Disparities in Healthcare-Associated Infections in the United States, 2009–2011
37. The Association between Age, Sex, and Hospital-Acquired Infection Rates: Results from the 2009–2011 National Medicare Patient Safety Monitoring System
38. 48 - Neumonía nosocomial
39. Association Between the Order of Macrolide and Cephalosporin Treatment and Outcomes of Pneumonia
40. The Prevalence and Significance of Staphylococcus aureus in Patients with Non-Cystic Fibrosis Bronchiectasis
41. Higher Priced Older Pharmaceuticals: How Should We Respond?
42. Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis: Results From an NTM Info & Research Patient Survey and the Bronchiectasis and NTM Research Registry
43. How to translate the new hospital-acquired and ventilator-associated pneumonia guideline to the bedside
44. Temporal trends in postoperative and ventilator-associated pneumonia in the United States
45. Analysis of Hospital-Level Readmission Rates and Variation in Adverse Events Among Patients With Pneumonia in the United States
46. Antibiotic resistance patterns in medical and surgical patients in a combined medical-surgical intensive care unit
47. Is the Present Definition of Health Care–Associated Pneumonia the Best Way to Define Risk of Infection with Antibiotic-Resistant Pathogens?
48. Does Value-Based Purchasing Enhance Quality of Care and Patient Outcomes in the ICU?
49. The Association of Long-term Macrolide Therapy and Nontuberculous Mycobacterial Culture Positivity in Patients With Bronchiectasis
50. 48 - Hospital-Acquired Pneumonia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.